Mylan N.V. (MYL) : Zacks Investment Research ranks Mylan N.V. (MYL) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 8 research analysts is 2.25, which indicates as a Buy.
Mylan N.V. (MYL) : 6 investment research analysts covering Mylan N.V. (MYL) have an average price target of $59.17 for the near short term. The highest target price given by the Brokerage Firm to the stock is $70 and the lowest target is $52 for the short term. Analysts expect the variance to be within $7.14 of the average price.
Mylan N.V. has lost 6% in the last five trading days and dropped 3.51% in the last 4 weeks. Mylan N.V. is up 7.49% in the last 3-month period. Year-to-Date the stock performance stands at -15.63%. Mylan N.V. (NASDAQ:MYL): On Tuesdays trading session , Opening price of the stock was $47.45 with an intraday high of $47.59. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $45.53. However, the stock managed to close at $45.62, a loss of 4.76% for the day. On the previous day, the stock had closed at $47.9. The total traded volume of the day was 13,105,383 shares.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.